To sum up, these findings suggest that Sirt6 may regulate the progression of DLBCL via activating the PI3K/Akt/mTOR and DNA damage response signaling pathway (Fig. 6f). This evidence concerns the gene MTOR and diffuse large B-cell lymphoma.